Table 2.

Changes in Clinical and Laboratory Parameters in NHAANS Participants Between First and Last Visit

	Full Sample		0/1 APOL1 Risk Variants		2 APOL1 Risk Variants
Variable Assessed for Change	N	Value	n	Value	n	Value	P
Systolic BP, mm Hg	650	3.0 [−7.5, 14.0]	489	2.0 [−8.5, 13.0]	161	6.0 [−3.5, 15.5]	0.01
Diastolic BP, mm Hg	650	0.0 [−8.0, 8.0]	489	0.0 [−8.0, 70]	161	1.5 [−9.0, 9.0]	0.2
BMI, kg/m2	653	0.2 [−1.5, 2.0]	490	0.03 [−1.7, 1.8]	163	0.4 [−0.9, 2.3]	0.03
Serum glucose, mg/dL	600	3.0 [−7.0, 14.0]	490	3.0 [−8.0, 14.0]	110	4.5 [−4.0, 16.0]	0.05
UACR, mg/g	664	1.0 [−2.2, 8.5]	495	0.7 [−2.6, 7.5]	169	2.2 [−1.1, 13.7]	0.03
Cystatin C, mg/L	651	0.0 [−0.1, 0.1]	490	0.02 [−0.05, 0.1]	161	−0.01 [−0.08, 0.05]	<0.001
eGFRcr, mL/min/1.73 m2	656	1.3 [−6.8, 10.2]	495	1.2 [−7.1, 9.7]	161	1.4 [−5.9, 10.5]	0.6
eGFRcr-cys, mL/min/1.73 m2	657	−3.0 [−9.6, 3.0]	490	−3.0 [ −9.7, 3.0]	167	−2.9 [−9.3, 2.8]	0.7
eGFRcys, mL/min/1.73 m2	657	0.0 [0.0, 0.1]	490	0.02 [−0.05, 0.1]	167	0.02 [−0.03, 0.09]	0.9

Note: Values given as median [interquartile range]. Median time between the baseline and final visit was 2.4 [2.3, 2.6] years in the APOL1 0/1 risk variant carriers and 3.4 [2.8, 3.6] years in the APOL1 2 risk variant carriers.